Exjade Related Clinical Trials
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload [Recruiting]
Exjade-Early-Trial [Recruiting]
Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both [Recruiting]
Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load [Not yet recruiting]
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload [Recruiting]
Safety, Tolerability, and Efficacy of Deferasirox in MDS [Recruiting]
Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload [Recruiting]
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis [Recruiting]
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload [Recruiting]
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda [Recruiting]
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload [Recruiting]
Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers [Completed]
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox. [Recruiting]
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload [Recruiting]
Combo Chelation Trial [Recruiting]
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload [Recruiting]
Cardiac T2* in Beta-Thalassemia Patients on Deferasirox Treatment [Active, not recruiting]
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload [Active, not recruiting]
Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-Thalassemia and Transfusional Hemosiderosis [Active, not recruiting]
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients [Active, not recruiting]
An Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia Patients With Transfusional Iron Overload [Active, not recruiting]
Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload [Active, not recruiting]
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis [Active, not recruiting]
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients [Active, not recruiting]
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food [Recruiting]
Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload [Active, not recruiting]
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload [Completed]
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload [Active, not recruiting]
Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam [Completed]
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study [Recruiting]
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox [Recruiting]
A 1-Year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis [Active, not recruiting]
Iron Chelation Therapy With Deferasirox in β-Thalassemia Major Pediatric Patients With Transfusional Iron Overload [Active, not recruiting]
ICL670 in Patients With Chronic Anemia and Transfusional Hemosiderosis [Recruiting]
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients [Active, not recruiting]
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study [Recruiting]
A Study of Long-Term Treatment With Deferasirox in Patients With Beta-Thalassemia and Transfusional Hemosiderosis [Completed]
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant [Recruiting]
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-Thalassaemia Patients) With Chronic Iron Overload [Recruiting]
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions [Completed]
Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec [Recruiting]
Safety & Efficacy of ICL670 Vs. Deferoxamine in Beta-Thalassemia Patients With Iron Overload Due to Blood Transfusions [Completed]
Study of Deferasirox in Iron Overload From Beta-Thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias [Completed]
Clinical Importance of Treating Iron Overload in Sickle Cell Disease [Recruiting]
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload [Recruiting]
|
